Pharmaceutical

Eculizumab biosimilar by Turgut Ilaclari for Neuromyelitis Optica (Devic’s Syndrome): Likelihood of Approval

Eculizumab biosimilaris under clinical development by Turgut Ilaclari and currently in Phase I for Neuromyelitis Optica (Devic’s Syndrome).

Jul 1, 2023 - 20:00
Eculizumab biosimilaris under clinical development by Turgut Ilaclari and currently in Phase I for Neuromyelitis Optica (Devic’s Syndrome).
Read the original article

Tags:

Previous Article

(Glucagon + insulin human) by Abvance Therapeutics for Hypoglycemia: Likelihood ...

Next Article

Pfizer’s Breakthrough Treatment for Severe Alopecia Areata in Adolescents Receiv...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Radiopharmaceuticals reach record high with $408m in venture financing for 2023

Radiopharmaceuticals reach record high with $408m in ve...

Nov 28, 2023

Opinion: Ohio has enshrined the right to an abortion. But major obstacles remain for patients and providers

Opinion: Ohio has enshrined the right to an abortion. B...

Nov 13, 2023

NIH funds expanded access projects for ALS

NIH funds expanded access projects for ALS

Oct 6, 2023